Real-Time Image-Guided Ablative Prostate Cancer Radiation Therapy: Results from the TROG 15.01 SPARK Trial

Kilovoltage Intrafraction Monitoring (KIM) is a novel software platform implemented on standard radiation therapy systems enabling real-time image-guided radiation therapy (IGRT). In a multi-institutional prospective trial, we investigated whether real-time IGRT improved the accuracy of the dose prostate cancer patients received during radiation therapy.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research

Related Links:

Condition:   Prostate Cancer Interventions:   Drug: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC;   Radiation: Stereotactic Body Radiation Therapy (SBRT) Sponsors:   Weill Medical College of Cornell University;   National Cancer Institute (NCI) Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: - Category: Research Source Type: clinical trials
Conclusions: CART-based machine learning multivariate analyses drawing from 910 dosimetric features and ADT use modestly improves upon clinical prediction of late GU toxicity alone, yielding an AROC of 0.601. Biologic predictors may enhance predictive models for identifying patients at risk for late toxicity after SBRT.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study extends the findings from a recent systematic review by the current authors which concentrated on tumour outcomes for PT, to now examine toxicity as a separate focus. Together, these reviews provide a comprehensive collation of the evidence relating to PT outcomes in clinical practice. Three major databases were searched by two independent researchers, and evidence quality was classified according to the National Health and Medical Research Council evidence hierarchy. One hundred and seventy ‐nine studies were included. Most demonstrated acceptable and favourable toxicity results. Comparative evidence reported...
Source: Journal of Medical Imaging and Radiation Oncology - Category: Radiology Authors: Tags: Radiation Oncology —Review Article Source Type: research
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® i...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Authors: Konat-Bąska K, Chicheł A, Staszek-Szewczyk U, Maciejczyk A, Matkowski R Abstract Purpose: Prostate and colorectal cancers are the first and the third most popular malignancies in male population, in which some patients may develop these tumors metachronously or synchronously. At present, there are no standard recommendations, and oncologists need to provide an optimal management for two different cancers with an acceptable risk of possible treatment of adverse effects. Material and methods: This case report presents the treatment of a 61-year-old patient suffering from synchronous prostate and rectal...
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Condition:   Prostate Adenocarcinoma Interventions:   Radiation: CT-guided Stereotactic Body Radiation Therapy;   Radiation: MRI-guided Stereotactic Body Radiation Therapy;   Other: Questionnaire Administration Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Biology | Cancer | Cancer & Oncology | Physics | Prostate Cancer | Radiation Therapy | Radiology